Cerenome (CNSY) Financials: Revenue & Earnings
CNSY$1.79+0.13 +7.83%
$13.59M
Market Cap
—
P/E
—
Forward P/E
—
Score
Cerenome (CNSY) Financials: Revenue & Earnings
CNSY price $1.79 +0.13 +7.83%
- Ticker
- CNSY
- Price
- $1.79
- Change
- +0.13 +7.83%
- Market cap ?
- $13.59M
- Beta ?
- 1.47
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
Fair value
CNSY fair value $33.02. Price $1.79. Price is 95% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 278.11K. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 1.5). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 7.59M. Net debt -7.94M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2027-02-25 | — | -0.95 | — | 1.55M |
| 2026-10-29 | — | -1.04 | — | 750.00K |
| 2026-08-14 | -1.31 | -0.88 | 411.00K | 1.11M |
| 2026-05-15 | -1.05 | -0.85 | 1.03M | 974.00K |
| 2026-03-12 | -0.83 | -0.80 | 1.36M | 1.23M |
| 2025-10-30 | -1.00 | -0.50 | 1.40M | 1.49M |
| 2025-08-14 | 0.50 | -2.25 | 1.39M | 1.49M |
| 2025-05-30 | -29.75 | -6.20 | 1.06M | 1.48M |
| 2025-03-27 | -9.50 | -12.42 | 1.40M | 1.50M |
| 2024-11-14 | -9.25 | -14.06 | 1.46M | 1.47M |
| 2024-08-14 | -112.50 | — | 1.28M | — |
| 2024-05-15 | -187.50 | — | 1.68M | — |
| 2024-03-05 | -212.50 | — | 1.31M | — |
| 2023-10-31 | -250.00 | — | 1.24M | — |
| 2023-08-14 | -147.50 | — | 1.85M | — |
| 2023-04-20 | -517.50 | — | 506.00K | — |
| 2023-02-23 | -640.00 | — | 151.00K | — |
| 2022-10-20 | -712.50 | — | 73.00K | — |
| 2022-07-21 | -89,000.00 | — | — | — |
| 2022-04-21 | -71,250.00 | — | — | — |
| 2022-02-24 | -101,250.00 | — | — | — |
| 2021-10-21 | -105,250.00 | — | — | — |
| 2021-07-22 | -93,000.00 | — | — | — |
| 2021-07-06 | -123,250.00 | — | — | — |
| 2021-02-22 | -250,500.00 | — | — | — |
| 2020-10-22 | -147,250.00 | — | — | — |
| 2020-08-10 | -1,702.50 | — | 185.00K | — |
| 2020-05-14 | -1,050.00 | — | 118.00K | — |
| 2020-03-30 | 855.00 | — | 1.19M | — |
| 2019-11-14 | -112.50 | — | 4.77M | — |
| 2019-08-15 | -77,512.50 | — | 302.00K | — |
| 2019-05-14 | -33,450.00 | — | 1.44M | — |
| 2019-03-29 | -28,270.00 | — | 2.13M | — |
| 2018-11-14 | -103,612.50 | — | 1.31M | — |
| 2018-08-14 | -110,625.00 | — | 1.56M | — |
| 2018-05-11 | -136,875.00 | — | 1.65M | — |
| 2018-03-09 | -196,687.50 | — | 1.53M | — |
| 2017-11-09 | -260,625.00 | — | 1.77M | — |
| 2017-08-11 | -363,750.00 | — | 1.50M | — |
| 2017-05-12 | -618,750.00 | — | 1.61M | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-01 | van Es-Johansson An | Buy | 921 | — | — |
| 2026-10-01 | van Es-Johansson An | Sell | 921 | — | — |
| 2026-10-01 | Hawkins Richard J | Buy | 921 | — | — |
| 2026-10-01 | Hawkins Richard J | Sell | 921 | — | — |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | Sell | 1.53K | — | — |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | Sell | 1.17K | — | — |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | Sell | 287 | — | — |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | Buy | 287 | — | — |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | Buy | 1.17K | — | — |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | Buy | 1.53K | — | — |
| 2026-10-01 | Clowes Howard | Buy | 921 | — | — |
| 2026-10-01 | Clowes Howard | Sell | 921 | — | — |
| 2026-10-01 | HEDRICK MARC H | Sell | 6.39K | — | — |
| 2026-10-01 | HEDRICK MARC H | Sell | 8.07K | — | — |
| 2026-10-01 | HEDRICK MARC H | Sell | 1.99K | — | — |
| 2026-10-01 | HEDRICK MARC H | Buy | 1.99K | — | — |
| 2026-10-01 | HEDRICK MARC H | Buy | 8.07K | — | — |
| 2026-10-01 | HEDRICK MARC H | Buy | 6.39K | — | — |
| 2026-10-01 | ANDREWS RONALD ASBURY | Buy | 921 | — | — |
| 2026-10-01 | ANDREWS RONALD ASBURY | Sell | 921 | — | — |
| 2026-10-01 | Guse Kyle | Buy | 921 | — | — |
| 2026-10-01 | Guse Kyle | Sell | 921 | — | — |
Institutional holders
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| No data yet. | ||||
Earnings and financials
Cerenome, Inc. (CNSY) trades at $1.79, with a market cap of $13.59M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn